Ganetespib AIDS lung cancer survival.
A randomized phase II clinical trial demonstrated that combining the second-generation heat shock protein 90 inhibitor ganetespib with docetaxel can boost overall survival in patients with advanced lung adenocarcinoma who started therapy more than six months after diagnosis.